Answers are grounded in this paper and cite their sources.
This study will inform dose selection for further clinical development and determine whether BI 690517, with or without background empagliflozin, has a favorable safety profile and potential for additive kidney protection in participants with CKD already treated with a renin-angiotensin system inhibitor.
No takes yet. Share an insight, caveat, or question.
Tuttle et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: